Food News and Research

RSS

BioMimetic Therapeutics reports net loss of $7.7M for second-quarter 2010

BioMimetic Therapeutics, Inc. today reported its financial results as of and for the three and six months ended June 30, 2010. For the three months ended June 30, 2010, the Company reported a net loss of $7.7 million, or $0.35 per diluted share, compared to a net loss of $6.3 million, or $0.32 per diluted share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $16.2 million, or $0.73 per diluted share, compared to a net loss of $14.3 million, or $0.75 per diluted share, for the same period in 2009.

6 Aug 2010

Child Nutrition Initiative encourages Senate for Healthy, Hunger-Free Kids Act

The Child Nutrition Initiative commends Sen. Blanche Lincoln (D-AR), Chairman of the U.S. Senate Agriculture, Nutrition, and Forestry Committee and ranking member Saxby Chambliss (R-GA) for their hard work and commitment to pass the bipartisan Healthy, Hunger-Free Kids Act (S. 3307) – a vital step in the effort to improve children's health and increase their access to nutritious school meals. We applaud the Senate for their strong bipartisan support and encourage the U.S. House to act quickly to pass similar legislation so critical improvements can be signed into law this year.

6 Aug 2010

Survey reveals need for nutrition education among African Americans for disease prevention, management

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.African Americans are 1.8 times more likely to develop Type 2 diabetes and 1.4 times more likely to be obese than are non-Hispanic whites, according to federal health agencies. Obesity is a leading risk factor for development of diabetes, a condition that results when the body cannot properly use insulin to transfer sugar from the blood to muscle and fat cells that use glucose for energy.

6 Aug 2010

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Shire plc, the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.

6 Aug 2010

New research on use of medicine, diet to prevent UV-induced skin cancer

In most cases, non-melanoma skin cancers are caused by overexposure to ultraviolet radiation - the invisible rays from the sun that can burn the skin. To reduce the risk of skin cancer, dermatologists encourage the public to Be Sun Smart, including limiting sun exposure and using broad-spectrum sunscreens.

6 Aug 2010

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Vaccines have a long history of successfully preventing disease and, in effect, improving the lives of countless Americans. Now, two serious diseases - human papillomavirus (HPV) and herpes zoster - could become a thing of the past as people better understand the safety and efficacy of vaccines to prevent these serious viral infections in specific populations.

6 Aug 2010

Patheon, Dendreon announce signing of technology transfer agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (sipuleucel-T) manufacturing process.

6 Aug 2010

House to return after Senate approves extension of enhanced Medicaid funds

House Speaker Nancy Pelosi will bring the House back from its recess next week to vote on an extension of enhanced state Medicaid funds the Senate is poised to approve as soon as Thursday afternoon, Politico reports.

6 Aug 2010

Agendia inaugurates new clinical genomics laboratory

Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.

6 Aug 2010

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

5 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

The U.S. Food and Drug Administration today issued two comprehensive evaluations containing recommendations that address three key objectives of the agency's public health mission as it relates to medical devices – foster device innovation, create a more predictable regulatory environment, and enhance device safety.

5 Aug 2010

New article highlights importance of patient safety features in design of IV needleless connectors

A new article by infection control expert William Jarvis, M.D., President, Jason and Jarvis Associates, LLC, highlights the importance of patient safety features in the design of IV needleless connectors.

5 Aug 2010

German Virtual Liver Network aims to grasp whole organ and functions in computer model

The aim of this unique research consortium is to grasp the whole organ and its functions in a computer model

5 Aug 2010

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

USP advances new labeling requirements to prevent errors in administration of injectable medications

To reduce the likelihood of patient death and disability resulting from errors in the administration of injectable medications in hospitals and other healthcare settings, the U.S. Pharmacopeial Convention is advancing new labeling requirements that will standardize the information permitted on the highly visible area of these vials to only cautionary statements intended to prevent imminent life-threatening situations.

5 Aug 2010

CEL-SCI produces and fills first lot of Multikine

CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.

5 Aug 2010

Censis launches ScopeTrac endoscope tracking and reprocessing data management solution

Censis® Technologies, Inc., developer of Censitrac™ surgical instrument tracking systems, has introduced ScopeTrac, an endoscope tracking and reprocessing data management solution designed to help prevent inappropriate endoscope reprocessing.

5 Aug 2010

Catalyst Health Solutions second-quarter 2010 net income up 21%

Catalyst Health Solutions, Inc., a pharmacy benefit management company, today announced its financial results for the quarter ended June 30, 2010. The Company reported quarterly net income of $19.5 million, up 21% compared to $16.2 million in the prior year. Earnings per diluted share increased by $0.07 to $0.44 from $0.37. Revenue for the quarter ended June 30, 2010, grew by 24% to $890.1 million from $717.6 million in the prior year.

5 Aug 2010

Food News and Research

BioMimetic Therapeutics reports net loss of $7.7M for second-quarter 2010

Child Nutrition Initiative encourages Senate for Healthy, Hunger-Free Kids Act

Survey reveals need for nutrition education among African Americans for disease prevention, management

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

New research on use of medicine, diet to prevent UV-induced skin cancer

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Patheon, Dendreon announce signing of technology transfer agreement

House to return after Senate approves extension of enhanced Medicaid funds

Agendia inaugurates new clinical genomics laboratory

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Incyte second-quarter total revenues increase to $49.8 million

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

FDA issues comprehensive evaluations that address key objectives of agency's public health mission

New article highlights importance of patient safety features in design of IV needleless connectors

German Virtual Liver Network aims to grasp whole organ and functions in computer model

BioCryst second-quarter total revenues increase to $7.6 million

USP advances new labeling requirements to prevent errors in administration of injectable medications

CEL-SCI produces and fills first lot of Multikine

Censis launches ScopeTrac endoscope tracking and reprocessing data management solution

Catalyst Health Solutions second-quarter 2010 net income up 21%

Understanding cultivated meat and its global potential eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News